Archive | Cancer in the News

FDA Grants Adjuvant Dabrafenib/Trametinib Priority Review for BRAF + Melanoma

The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of dabrafenib (Tafinlar) combined with trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Read the full story

Posted in Melanoma In The News, FDA

FDA Greenlights Nivolumab as an Adjuvant Melanoma Therapy

Yesterday, nivolumab (Opdivo) was granted regular approval for the treatment of patients with melanoma whose disease spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.

Read the full story

Posted in Melanoma In The News, FDA

Dabrafenib/Trametinib Granted Priority Review for Stage III BRAF-Mutated Melanoma

The US Food and Drug Administration (FDA) has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations after complete disease resection.

Read the full story

Posted in Melanoma In The News, FDA

Melanoma Journal Articles for November 2017

The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts.

Read the full story

Posted in Journal Articles

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories